Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer.

Cancer chemotherapy and pharmacology - 1 May 2013

Sudo Makoto, Chin Tan Min, Mori Seiichi, Doan Ngan B, Said Jonathan W, Akashi Makoto, Koeffler H Phillip

Abstract excerpt

PURPOSE: Sensitivity to a tyrosine kinase inhibitor (TKI) is correlated with the presence of somatic mutations that affect the kinase domain of epidermal growth factor receptor (EGFR). Development of resistance to TKI is a major therapeutic problem in non-small cell lung cancer (NSCLC). Aim of th...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzoquinones
Share to Drug Synergism
Share to Gefitinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydroxamic Acids

Share to Lactams, Macrocyclic

Share to PTEN Phosphohydrolase

Share to Quinazolines

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 23515752
DOI: 10.1007/s00280-013-2132-y
PMCID: PMC3636434

Genes

EGFR
PTEN

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23515752-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer.PMID 23515752Read ↗

The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer.Semantic proximity Read ↗

Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib.Semantic proximity Read ↗

The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor.Semantic proximity Read ↗

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer.Semantic proximity Read ↗

Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells.Semantic proximity Read ↗

EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.Semantic proximity Read ↗

Downregulated ABCG2 enhances sensitivity to topoisomerase I inhibitor in epidermal growth factor receptor tyrosine kinase inhibitor-resistant non-small cell lung cancer.Semantic proximity Read ↗

Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.Semantic proximity Read ↗

AZD9291 Increases Sensitivity to Radiation in PC-9-IR Cells by Delaying DNA Damage Repair after Irradiation and Inducing Apoptosis.Semantic proximity Read ↗

Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.Semantic proximity Read ↗

Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo.Semantic proximity Read ↗

Enhanced gefitinib-induced repression of the epidermal growth factor receptor pathway by ataxia telangiectasia-mutated kinase inhibition in non-small-cell lung cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.